Evidence map›Paper›PMID 29696234›Full record

ArticleContemporary clinical trials communications2018

Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.

T van Doeveren, P J van Leeuwen, K K H Aben, M van der Aa, M Barendrecht, E R Boevé, E B Cornel, A G van der Heijden, K Hendricksen, W Hirdes and 11 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

T van DoeverenErasmus University Medical Center, Rotterdam, The Netherlands.
P J van LeeuwenErasmus University Medical Center, Rotterdam, The Netherlands.
K K H AbenNetherlands Comprehensive Cancer Organisation, The Netherlands.
M van der AaSpaarne Medical Center, Hoofddorp, The Netherlands.
M BarendrechtTergooi Medical Center, Hilversum, The Netherlands.
E R BoevéFransiscus Medical Center, Rotterdam, The Netherlands.
E B CornelZiekenhuis Groep Twente, Almelo and Hengelo, The Netherlands.
A G van der HeijdenRadboud University Medical Center, Nijmegen, The Netherlands.
K HendricksenNetherlands Cancer Institute, Amsterdam, The Netherlands.
W HirdesIsala Medical Center, Zwolle, The Netherlands.
A KooistraMeander Medical Center, Amersfoort, The Netherlands.
B KroonRijnstate Medical Center, Arnhem, The Netherlands.
A M LeliveldUniversity Medical Center Groningen, Groningen, The Netherlands.
R P MeijerUniversity Medical Center Utrecht, Utrecht, The Netherlands.
H van MelickSint Antonius Medical Center, Nieuwegein, The Netherlands.
B MerksHaaglanden Medical Center, Leidschendam, The Netherlands.
T M de ReijkeAcademic Medical Center, Amsterdam, The Netherlands.
P de VriesZuyderland Medical Center, Heerlen, The Netherlands.
L F A WymengaMartini Medical Center, Groningen, The Netherlands.
B WijsmanElisabeth-TweeSteden Medical Center, Tilburg, The Netherlands.
J L BoormansErasmus University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLRadboud University Nijmegen · NLAmsterdam UMC Location University of Amsterdam · NLElisabeth-TweeSteden Ziekenhuis · NLIsala · NLMartini Ziekenhuis · NLMeander Medisch Centrum · NLMedisch Centrum Haaglanden · NLRijnstate Hospital · NLSint Franciscus Gasthuis · NLSpaarne Ziekenhuis · NLSt. Antonius Ziekenhuis · NLTergooi · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NLZiekenhuis Groep Twente · NLZuyderland Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing radical nephro-ureterectomy for urothelial carcinoma of the upper urinary tract (UUT), the reported bladder recurrence rate of urothelial carcinoma is 22-47%. A single intravesical instillation of chemotherapy within 10 days following nephro-ureterectomy has the potential to decrease the risk of a bladder recurrence significantly. Despite recommendation by the European Association of Urology guideline to administer a single instillation postoperatively, the compliance rate is low because the risk of extravasation of chemotherapy.

aimTo reduce the risk of bladder cancer recurrence by a single intravesical instillation of Mitomycin immediately (within 3 h) before radical nephro-ureterectomy or partial ureterectomy.

methodsAdult patients (age ≥ 18 years) with a (suspicion of a) urothelial carcinoma of the UUT undergoing radical nephro-ureterectomy or partial ureterectomy will be eligible and will receive a single intravesical instillation of Mitomycin within 3 h before surgery. In total, 170 patients will be included in this prospective, observational study. Follow-up will be according to current guidelines.

resultsThe primary endpoint is the bladder cancer recurrence rate up to two years after surgery. Secondary endpoints are: a) the compliance rate; b) oncological outcome; c) possible side-effects; d) the quality of life; e) the calculation of costs of a single neoadjuvant instillation with Mitomycin and f) molecular characterization of UUT tumors and intravesical recurrences.

conclusionsA single intravesical instillation of Mitomycin before radical nephro-ureterectomy or partial ureterectomy may reduce the risk of a bladder recurrence in patients treated for UUT urothelial carcinoma and will circumvent the disadvantages of current therapy.

Indexed as

Bladder cancerChemotherapyNephro-ureterectomyUpper urinary tractUrothelial carcinoma

Identifiers

PMID29696234
PMCPMC5898538
OpenAlexW2794315407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.